Puja Sapra, Director, Oncology Research Unit at Pfizer Will Give a Featured Presentation at the 5th ImmunoTherapeutics & ImmunoMonitoring Conference (Jan 31 - Feb 1, 2013 in San Diego)

MONROVIA, CA, October 06, 2012 (Press-News.org) Puja Sapra, Director, Oncology Research Unit at Pfizer Will Give a Featured Presentation on "Design Considerations For Development of an Optimal Antibody-Drug Conjugate" at the 5th ImmunoTherapeutics & ImmunoMonitoring Conference (Jan 31 - Feb 1, 2013 in San Diego)

Antibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical management of cancer. Dr. Puja Sapra will use case studies to elaborate on the multifaceted optimization required to yield a viable clinical candidate ADC. ADCs employing different mechanism of action (MOA) payloads will be used as examples to illustrate the need to match target biology with MOA of payload. Further, an update on clinical data of CMC-544, an anti-CD22 calicheamicin conjugate will be provided. Additionally, innovations and approaches in ADC development at Pfizer Oncology Research will be described.

Dr. Puja Sapra is the Director at Oncology Research Unit, Pfizer and oversees all antibody drug conjugate therapeutic programs at Pfizer ORU. Before joining Pfizer, Dr. Sapra led Pharmacology groups at Enzon Pharmaceuticals and Immunomedics Inc. and developed several oncology-based drugs that are undergoing clinical evaluation including anti-CD22 mAb, CD74-doxorubicin ADC, pegylated-SN38 drug conjugate, HIF1α, survivin and androgen receptor antisense oligonucelotides. Dr. Sapra is an author of over 40 scientific publications, book chapters or patents and recipient of several scholarships and grants including British Chevening scholarship, Alberta Foundation grant, NIH SBIR grant, European hematology association young investigator award.


Network with clinical immunologists, pathologists, and pharmacologists, as well as practicing clinicians and R&D scientists, to discuss the newest development in the field. Leading experts from the scientific and clinical arenas and industry will present about novel findings and developments in the constantly changing area of immunological assays and procedures. They will also discuss recent advances in immunotherapy, as they relate to various immunotherapy modalities, specific cancers, cell subsets, animal models, and tumor microenvironment. Potential clinical feasibility and commercial potential of the newest data obtained from leading biomedical research laboratories will also be discussed.

One would also learn about:
• An update of the state of the art in immunomonitoring
• Novel strategies to identify and validate biomarkers predictive for clinical efficacy
• Novel strategies to identify and clinically develop synergistic combination therapies
• Outlook on novel druggable targets for immunotherapy

This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of three other concurrent conferences:

2nd Novel Immunotherapeutics Summit:
Track: 5th Immunotherapeutics & Immunomonitoring
Track: 11th Cytokines & Inflammation
Track: 2nd Allergy Research & Drug Discovery
Track: Immunotoxicity & Immunogenicity


To view the Program Agenda Click Here. To view the updated Speaker List Click Here

For more information, please visit http://www.gtcbio.com

ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com